rolipram has been researched along with MPTP Neurotoxicity Syndrome in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cognitive impairment often occurs in Parkinson's disease (PD), but the mechanism of onset remains unknown." | 1.46 | Rolipram improves facilitation of contextual fear extinction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease. ( Ishii, T; Kinoshita, KI; Muroi, Y; Unno, T, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kinoshita, KI | 1 |
| Muroi, Y | 1 |
| Unno, T | 1 |
| Ishii, T | 1 |
| Yang, L | 1 |
| Calingasan, NY | 1 |
| Lorenzo, BJ | 1 |
| Beal, MF | 1 |
2 other studies available for rolipram and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
Rolipram improves facilitation of contextual fear extinction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cyclic AMP; Cyclic AMP Resp | 2017 |
Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Dose-Response Relationshi | 2008 |